Antibodies against ErbB3 and uses thereof

Details Antibodies against ErbB3 and uses thereof Antibodies against ErbB3 and uses thereof

2008-02-15

2010-12-07

Bristol, Lynn (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S388100

Reexamination Certificate

active

07846440

ABSTRACT:
The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. In a particular embodiment, the antibodies are capable of binding to ErbB3 and inhibiting ligand mediated phosphorylation of the receptor.

REFERENCES:
patent: 5344760 (1994-09-01), Harvey et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 6696290 (2004-02-01), Fitzpatrick et al.
patent: 6983227 (2006-01-01), Thalhammer-Reyero
patent: 7097840 (2006-08-01), Erickson et al.
patent: 7125680 (2006-10-01), Singer et al.
patent: 7285649 (2007-10-01), Akita et al.
patent: 2002/0001587 (2002-01-01), Erickson et al.
patent: 2002/0002276 (2002-01-01), Fitzpatrick et al.
patent: 2002/0119148 (2002-08-01), Gerritsen et al.
patent: 2002/0165193 (2002-11-01), Greene et al.
patent: 2003/0040605 (2003-02-01), Siegel
patent: 2003/0199020 (2003-10-01), Fitzpatrick et al.
patent: 2004/0052786 (2004-03-01), Gerritsen et al.
patent: 2004/0082510 (2004-04-01), Ullrich et al.
patent: 2004/0138417 (2004-07-01), Fitzpatrick et al.
patent: 2004/0197332 (2004-10-01), Ullrich et al.
patent: 2004/0229380 (2004-11-01), Chan-Hui et al.
patent: 2004/0248151 (2004-12-01), Bacus et al.
patent: 2004/0248196 (2004-12-01), Adams et al.
patent: 2005/0004018 (2005-01-01), Jimeno et al.
patent: 2005/0187745 (2005-08-01), Lurie et al.
patent: 2005/0267720 (2005-12-01), Hill et al.
patent: 2006/0040363 (2006-02-01), Kucherlapati et al.
patent: 2006/0093603 (2006-05-01), Gerritsen et al.
patent: 2006/0136139 (2006-06-01), Elcock et al.
patent: 2006/0167637 (2006-07-01), Agur et al.
patent: 2006/0204505 (2006-09-01), Sliwkowski et al.
patent: 2006/0210561 (2006-09-01), Baughman et al.
patent: 2007/0059785 (2007-03-01), Bacus et al.
patent: 2007/0081994 (2007-04-01), Fitzpatrick et al.
patent: 2007/0092513 (2007-04-01), Gerritsen et al.
patent: 2007/0122407 (2007-05-01), Akita et al.
patent: 2007/0134251 (2007-06-01), Ashkenazi et al.
patent: 2007/0134252 (2007-06-01), Bacus et al.
patent: 2007/0190583 (2007-08-01), Spector et al.
patent: 2007/0254295 (2007-11-01), Harvey et al.
patent: 2008/0026415 (2008-01-01), Rimm et al.
patent: 2008/0057064 (2008-03-01), Zhou
patent: 2008/0090233 (2008-04-01), Garcia et al.
patent: 2008/0112958 (2008-05-01), Mass
patent: 2008/0124334 (2008-05-01), Akita et al.
patent: 2008/0124345 (2008-05-01), Rothe et al.
patent: 2008/0187948 (2008-08-01), Chan-Hui et al.
patent: 2008/0207615 (2008-08-01), Bell et al.
patent: 2008/0214584 (2008-09-01), Ohta et al.
patent: 2008/0254497 (2008-10-01), Singh
patent: 2009/0181022 (2009-07-01), Nielsen et al.
patent: 2009/0246206 (2009-10-01), Nielsen et al.
patent: 2009/0291085 (2009-11-01), Schoeberl et al.
patent: 1058562 (2000-12-01), None
patent: 1187634 (2002-03-01), None
patent: 1283053 (2003-02-01), None
patent: WO-97/35885 (1997-10-01), None
patent: WO-98/02540 (1998-01-01), None
patent: WO-99/54800 (1999-10-01), None
patent: WO-99/60023 (1999-11-01), None
patent: WO-00/78347 (2000-12-01), None
patent: WO-02/060470 (2002-08-01), None
patent: WO-03/012072 (2003-02-01), None
patent: WO-03/013602 (2003-02-01), None
patent: WO-2005/017493 (2005-02-01), None
patent: WO-2006/017538 (2006-02-01), None
patent: WO-2006/020706 (2006-02-01), None
patent: WO-2006/044748 (2006-04-01), None
patent: WO-2006/091209 (2006-08-01), None
patent: WO-2007/039705 (2007-04-01), None
patent: WO-2007/041502 (2007-04-01), None
patent: WO-2007/077028 (2007-07-01), None
patent: WO-2007/115571 (2007-10-01), None
patent: WO-2007/130677 (2007-11-01), None
patent: WO-2008/064884 (2008-06-01), None
patent: WO-2008/109440 (2008-09-01), None
Aaronson, S.A. et al., “Growth factor-regulated pathways in epithelial cell proliferation,”Am. Rev. Respir. Dis., vol. 142(6 pt. 2):S7-S10 (1990).
Alberts, Bruce et al., Molecular Biology of the Cell, Third Edition, Garland Publishing, Inc., New York, pp. 897-899 (1994).
Alimandi, Maurizio et al., “Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas,”Oncogene, vol. 10:1813-1821 (1995).
Alimandi, Maurizio et al., “Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 adn ErbB3 receptors,”The EMBO Journal, vol. 16(18):5608-5617 (1997).
Balint, Robert F. et al., “Antibody engineering by parsimonious mutagenesis,”Gene, vol. 137:109-118 (1993).
Beerli, Roger R. et al., “Neu Differentiation Factor Activation of ErbB-3 and ErbB-4 Is Cell Specific and Displays a Differential Requirement for ErbB-2,”Molecular and Cellular Biology, vol. 15(12):6496-6505 (1995).
Bodey, Bela et al., “Immunophenotypically Varied Cell Subpopulations in Primary and Metastatic Human Melanomas. Monoclonal Antibodies for Diagnosis, Detection of Neoplastic Progression and Receptor Directed Immunotherapy,”Anticancer Research, vol. 16:517-532 (1996).
Bostwick, David G., “c-erbB-2 Oncogene Expression in Prostatic Intraepithelial Neoplasia: Mounting Evidence for a Precursor Role,”Journal of the National Cancer Institute, vol. 86(15):1108-1110 (1994).
Brotherick, Ian et al., “A flow cytometric study of c-erbB-3 expression in breast cancer,”Cancer Immunol. Immunother., vol. 41:280-286 (1995).
Carraway, Kermit L. III et al., “A Neu Acquaintance for ErbB3 and ErbB4: A Role for the Receptor Heterodimerization in Growth Signaling,”Cell, vol. 78:5-8 (1994).
Carraway, Kermit L. III et al., “Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected witherbB2
euanderbB3,” The Journal of Biological Chemistry, vol. 270(13):7111-7116 (1995).
Carraway, Kermit L. III et al., “TheerbB3Gene Product Is a Receptor for Heregulin,”The Journal of Biological Chemistry, vol. 269(19):14303-14306 (1994).
Chen, Xiaomei et al., “An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4,”The Journal of Biological Chemistry, vol. 271(13):7620-7629 (1996).
Ciardiello, Fortunato et al., “Differential expression of epidermal growth factor-related proteins in human colorectal tumors,”Proc. Natl. Acad. Sci. USA, vol. 88:7792-7796 (1991).
Davies, Jullian et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,”Immunotechnology, vol. 2:169-179 (1996).
Di Fiore, Pier Paolo et al., “Mechanisms involving an expandingerbB/EGF receptor family of tyrosine kinases in human neoplasia,”Genes, Oncogenes, and Hormones, Robert B. Dickson, Ed., Kluwer Academic Publishers, pp. 139-160 (1992).
Drebin, Jeffrey A. et al., “Monoclonal antibodies reactive with distinct domains of theneuoncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo,”Oncogene, vol. 2:273-277 (1988).
Eccles, Suzanne A. et al., “Significance of thec-erbBFamily of Receptor Tyrosine Kinases in Metastatic Cancer and Their Potential as Targets for Immunotherapy,”Invasion Metastasis, vol. 14:337-348 (1995).
Ethier, Stephen P. et al., “erbB Family Receptor Expression and Growth Regulation in a Newly Isolated Human Breast Cancer Cell Line,”Cancer Research, vol. 56:899-907 (1996).
Faksvåg, Dagny R. et al., “Expression of c-erbB-3 and c-erbB-4 Proteins in Papillary Thyroid Carcinomas,”Cancer Research, vol. 56:1184-1188 (1996).
Fendly, Brian M. et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
euGene Product,”Cancer Research, vol. 50:1550-1558 (1990).
Fiddes, Rodney J. et al., “Heregulin (HRG)-induced Mitogenic Signaling and Cytotoxic Activity of a HRG/PE40 Ligand Toxin in Human Breast Cancer Cells,”Cell Growth&Differentiation, vol. 6:1567-1577 (1995).
Fitzpatrick, V. Danial et al., “Formation of a high affinity heregulin binding site

Affiliated with

Also associated with

Rating

Antibodies against ErbB3 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies against ErbB3 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against ErbB3 and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4233279